4D Molecular Therapeutics Inc

FDMT · NASDAQ · Healthcare / Biotechnology

12.23USD+0.12 (+0.95%)

Price History

Full chart

Market Stats

Previous Close12.12

Open11.62

Day Range10.98 – 12.37

52-Week Range6.96 – 16.93

Volume813.80K

Market Cap812.64M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.58

Dividend Yield0.00%

Beta2.73

50-Day Avg13.01

200-Day Avg10.34

About

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. David H. Kirn M.D.
Employees196
Headquarters5858 Horton Street, EmeryVille, CA, United States, 94608, USA
Websitehttps://www.4dmoleculartherapeutics.com

Leadership

Dr. John F. Milligan Ph.D.Executive Chairman · b. 1961
Dr. David H. Kirn M.D.Co-Founder, President, CEO & Director · b. 1962
Mr. Kristian Humer M.B.A.CFO and Principal Financial & Accounting Officer · b. 1976
Dr. Fariborz Kamal Ph.D.Chief Technical Advisor · b. 1963
Ms. Theresa JankeCo-Founder & Chief of Staff · b. 1975
Julian PeiHead of Investor Relations & Corporate Finance
Dr. Katy Barglow Ph.D.Chief Technical Officer
Dr. Scott P. Bizily J.D., Ph.D.Chief Legal Officer & Corporate Secretary · b. 1972
Dr. An Song Ph.D.Chief Translational Medicine Advisor
Dr. Noriyuki Kasahara M.D., Ph.D.Chief Scientific Advisor · b. 1963

Financials

Income Statement

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	5.79M	14.13M	6.99M	13.61M	18.04M	3.13M	20.72M	37.00K	85.21M
Growth (%)	-	+144.04%	-50.56%	+94.85%	+32.52%	-82.65%	+562.29%	-99.82%	+230194.59%
Cost of Revenue	13.57M	18.36M	38.72M	53.04M	3.02M	3.88M	97.10M	141.30M	7.63M
Gross Profit	-7.78M	-4.23M	-31.73M	-39.43M	18.04M	3.13M	-76.37M	-141.26M	77.58M
Gross Margin	-134.42%	-29.95%	-454.22%	-289.64%	100.00%	100.00%	-368.54%	-381789.19%	91.05%
Operating Expense	3.49M	6.17M	19.03M	17.24M	89.37M	113.16M	36.49M	46.58M	237.13M
Operating Income	-11.27M	-10.40M	-50.76M	-56.66M	-71.33M	-110.03M	-112.87M	-187.84M	-159.55M
Operating Margin	-194.68%	-73.60%	-726.65%	-416.28%	-395.46%	-3516.52%	-544.65%	-507678.38%	-187.24%
EBITDA	-10.65M	-9.70M	-44.62M	-55.22M	-68.31M	-106.15M	-96.63M	-154.16M	-132.48M
EBITDA Margin	-183.87%	-68.66%	-638.75%	-405.68%	-378.72%	-3392.52%	-466.31%	-416656.76%	-155.48%
Net Income	-11.22M	-9.55M	-49.31M	-56.69M	-68.30M	-101.08M	-100.84M	-160.87M	-140.11M
Net Income Margin	-193.83%	-67.59%	-705.78%	-416.49%	-378.63%	-3230.30%	-486.59%	-434778.38%	-164.43%
R&D	13.57M	18.36M	43.85M	53.04M	61.36M	80.25M	97.10M	141.30M	195.70M
R&D as % of Total Revenue	234.42%	129.95%	627.76%	389.64%	340.17%	2564.81%	468.54%	381889.19%	229.67%
Interest Expense	0	0	0	152.00K	3.04M	6.42M	-	-	-
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	1.12%	16.83%	205.11%	-	-	-

Balance Sheet

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	27.32M	96.97M	58.23M	288.33M	353.49M	261.85M	339.89M	560.38M	566.71M
Total Liabilities	46.91M	124.56M	131.20M	31.94M	34.38M	30.51M	32.06M	49.78M	61.05M
Total Equity	-19.59M	-27.59M	-72.97M	256.39M	319.11M	231.34M	307.83M	510.61M	505.66M
Cash	23.85M	91.76M	49.65M	276.73M	153.00M	52.35M	249.11M	149.34M	60.24M
Total Debt	-	-	-	-	16.45M	16.12M	14.67M	24.61M	21.41M
Net Debt	-23.85M	-91.76M	-49.65M	-276.73M	-136.55M	-36.23M	-234.44M	-124.73M	-38.83M

Cash Flow

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	8.24M	-16.25M	-36.71M	-50.91M	-69.13M	-86.69M	-75.79M	-134.59M	-109.08M
Investing Cash Flow	7.67M	-414.00K	-3.20M	-1.00M	-172.68M	-17.05M	115.72M	-302.44M	-92.97M
Financing Cash Flow	16.00K	84.58M	-2.19M	278.98M	118.09M	3.08M	156.83M	337.25M	112.96M
Capital Expenditure	573.00K	414.00K	3.20M	1.00M	9.11M	11.54M	2.77M	3.79M	536.00K
Free Cash Flow	7.66M	-16.67M	-39.91M	-51.91M	-78.24M	-98.22M	-78.56M	-138.37M	-109.08M
FCF to OCF	93.04%	102.55%	108.72%	101.96%	113.18%	113.31%	103.66%	102.81%	100.00%

Earnings

Report Date	Mar 31, 2018	Jun 30, 2018	Sep 30, 2018	Dec 31, 2018	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Dec 16, 2020	Mar 25, 2021	May 13, 2021	Aug 12, 2021	Nov 10, 2021	Mar 28, 2022	May 12, 2022	Aug 11, 2022	Nov 8, 2022	Mar 15, 2023	May 10, 2023	Aug 9, 2023	Nov 9, 2023	Feb 29, 2024	May 9, 2024	Aug 8, 2024	Nov 13, 2024	Feb 26, 2025	May 8, 2025	Aug 11, 2025	Nov 10, 2025	Feb 27, 2026	May 7, 2026	Aug 13, 2026	Nov 9, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.40	-0.66	-1.10	-0.68	-0.80	-0.86	-0.77	-0.85	-0.91	-0.79	-0.90	-0.77	-0.60	-0.74	-0.76	-0.71	-0.70	-0.84	-0.86	-0.69	-0.98	-0.53	-1.00	-1.04	-1.03
EPS Actual	-0.52	-0.52	-0.43	-0.43	-1.61	-1.61	-1.82	-3.12	-3.07	-2.36	-0.61	-0.28	-0.82	-0.85	-0.82	-0.87	-0.79	-0.84	-0.88	-0.77	-0.24	-0.75	-0.66	-0.63	-0.79	-0.90	-0.86	-0.98	-1.01	0.43	-1.01	-1.04	-
Surprise	-	-	-	-	-	-	-	-	-667.50%	-257.58%	44.55%	58.82%	-2.50%	1.16%	-6.49%	-2.35%	13.19%	-6.33%	2.22%	0.00%	60.00%	-1.35%	13.16%	11.27%	-12.86%	-7.41%	0.00%	-42.03%	-3.06%	180.83%	-1.00%	0.00%	-
Timing	-	-	-	-	-	-	-	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	Pre-market	Pre-market	-	After-hours	After-hours	-

Key Statistics & Ratios

Market Cap812.64M

Enterprise Value505.99M

Trailing P/E0.00

Forward P/E0.00

Price / Sales8.83

Price / Book2.03

EPS-2.58

Book Value7.38

Revenue (TTM)92.01M

Gross Profit (TTM)-145.10M

EBITDA-188.89M

Profit Margin-194.74%

Operating Margin-2037.16%

Return on Equity-43.25%

Return on Assets-25.09%

Shares Outstanding55.24M

Shares Float42.49M

Beta2.73

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 12 analystsTarget 27.82

Strong Buy
5
Buy
4
Hold
2
Strong Sell
1

Ownership Breakdown

Institutions: 105.91%
Insiders: 2.93%
Retail / Other: 0.00%

Top Institutional Holders

HHG PLC
5.25M9.50%
RA Capital Management, LLC
5.05M9.14%
The Goldman Sachs Group Inc
4.21M7.61%
BlackRock Inc
4.15M7.50%
Novo A/S
3.65M6.61%
Bvf Inc
2.88M5.21%
State Street Corp
2.71M4.90%
Adage Capital Partners Gp LLC
2.25M4.07%
Trails Edge Capital Partners, LP
2.23M4.03%
Vanguard Capital Management, LLC
2.20M3.97%
Armistice Capital, LLC
2.00M3.62%
Geode Capital Management, LLC
1.07M1.93%
Bank of America Corp
974.17K1.76%
Parkman Healthcare Partners LLC
948.18K1.72%

Top Fund Holders

State Street® SPDR® S&P® Biotech ETF
1.70M3.07%
Vanguard MStar Total Stk Mkt Idx Invest
1.59M2.88%
iShares Russell 2000 ETF
1.18M2.14%
T. Rowe Price Small-Cap Stock
917.56K1.66%
Janus Henderson Hrzn Biotec E2 USD
904.51K1.64%
Janus Henderson Global Life Sciences D
865.42K1.57%